PT-141 Dosage in the Research Literature

The FDA-approved dose is 1.75 mg subcutaneous per event. This page summarizes the dosing data from the published literature: the approved regimen, the Phase 2 intranasal history, pharmacokinetic parameters, onset and duration data, and frequency constraints from the clinical program.

The FDA-labeled dose of bremelanotide is 1.75 mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Maximum one dose per 24-hour period. Maximum eight doses per month. Discontinuation is recommended after 8 weeks without benefit ^[6].

This dosing regimen was established through the Phase 2b dose-ranging study (0.75, 1.25, 1.75 mg SC), in which 1.75 mg was the dose that achieved statistically significant improvement across all 7 pre-specified endpoints versus placebo (p≤0.03) in premenopausal women with HSDD ^[13]. The lower doses showed numerically smaller improvements that did not meet p-value thresholds across all endpoints, establishing 1.75 mg as the minimum effective dose for the registration program.

The drug is contraindicated in subjects with uncontrolled hypertension or known cardiovascular disease ^[8]. PT-141 is not approved for use in men, postmenopausal women, or any indication other than HSDD in premenopausal women.

Phase 1 and Phase 2 studies tested intranasal delivery as the primary route. Dose-escalation in healthy males and men with mild-to-moderate ED identified doses above 7 mg intranasal as the threshold for statistically significant erectile response versus placebo, with onset approximately 30 minutes post-administration ^[1]. No maximum tolerated dose was reached in the tested intranasal range.

A 20 mg single intranasal dose in premenopausal women with sexual arousal disorder produced significantly increased subjective desire and arousal satisfaction versus placebo in a double-blind Phase 2 study ^[3]. This was an earlier exploratory dose; the Phase 2b program then examined lower subcutaneous doses (0.75–1.75 mg SC) to establish an approvable safety-to-efficacy window.

The intranasal formulation was ultimately discontinued due to bioavailability variance. Subcutaneous administration provided 100% bioavailability and consistent exposure at the 1.75 mg dose ^[7], which drove the Phase 3 decision to use the subcutaneous auto-injector that became the approved product.

Plasma half-life of bremelanotide in human pharmacokinetic studies is approximately 2.5 hours (range 1.9–2.7 hours across studies) ^[7]. In early intranasal Phase 1 studies, half-life values of 1.85–2.09 hours were reported ^[1].

Peak plasma concentration (Tmax) occurs approximately 0.5–1.0 hours post subcutaneous injection. After 1.75 mg SC, peak plasma concentration is approximately 72.8 ng/mL. Clearance is 6.5 ± 1.0 L/h. Protein binding is 21%. Metabolism occurs via multiple hydrolysis reactions (cellular peptidase digestion). Excretion is primarily renal (64.8%) with fecal clearance at 22.8% ^[7].

Duration of pharmacodynamic effects in clinical trial subjects has been characterized as approximately 6–12 hours based on event-diary assessments. Blood pressure effects (transient systolic increase) resolved within 12 hours ^[8].

Clinical trial data indicates effects lasting approximately 6–12 hours in human subjects, with onset typically 30–60 minutes after subcutaneous administration ^{[7] [8]}. Duration varies by dose and individual response in study subjects. The blood pressure monitoring program documented that transient systolic increases typically resolved within 12 hours, providing a pharmacodynamic window consistent with the label's 24-hour minimum inter-dose interval.

In Phase 3 trials, subjects reported onset of effect approximately 30–60 minutes after subcutaneous injection, consistent with the pharmacokinetic Tmax of 0.5–1.0 hours ^[7]. The approved product instructs administration at least 45 minutes before anticipated sexual activity — reflecting the median onset from clinical data. Intranasal formulations studied in earlier phases showed a slightly faster onset but shorter duration and were dropped due to bioavailability variance ^{[1] [7]}.

The approved bremelanotide dosing regimen specifies no more than one dose per 24 hours and a maximum of 8 doses per month ^[6]. This frequency constraint is driven by two observations from the clinical program.

First, the transient blood pressure increase documented with each dose ^[8] motivates a minimum inter-dose interval. Second, hyperpigmentation — an MC1R-mediated adverse event — was observed in over one-third of subjects receiving consecutive daily doses for 16 days in research protocols, but was rare at the label-compliant dosing frequency ^[9]. The safety database of 3,500 subjects across 43 studies, including a 52-week open-label extension, provides the basis for confidence in the label-compliant frequency; chronic high-frequency dosing data beyond that program is limited ^[14].

Three routes were studied across the bremelanotide development program: intravenous (Phase 1 safety only), intranasal (Phase 1–2 dose-finding), and subcutaneous (Phase 2b and Phase 3 registration, and the approved product). Intravenous administration confirmed the compound's pharmacokinetic profile and safety at low doses. Intranasal delivery provided faster onset but inconsistent bioavailability across subjects, leading to its discontinuation in Phase 3. Subcutaneous administration — delivered via an auto-injector into the abdomen, thigh, or upper arm — provided 100% bioavailability and was the route that generated the Phase 3 efficacy data supporting approval ^[7]. The approved Vyleesi product uses subcutaneous delivery exclusively.

For the full adverse-event profile across the dosing program, see PT-141 side effects. For the mechanism underlying these dose-response relationships, see PT-141 mechanism of action.